Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 518-523

  Carnathan, Diane G ^a   Wetzel, Katherine S ^a   Yu, Joana ^a   Lee, S Thera ^a   Johnson, Brent A ^b   Paiardini, Mirko ^a   Yan, Jian ^c   Morrow, Matthew P ^c   Sardesai, Niranjan Y ^c   Weiner, David B ^d   Ertl, Hildegund C J ^e   Silvestri, Guido ^a   Gallo, Robert C ^f  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Inovio Pharmaceuticals   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WISTAR INSTITUTE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CD4; HIV; SIV; Vaccination

Indexed keywords

ADENOVIRUS VACCINE; CHEMOKINE RECEPTOR CCR5; CHIMPANZEE ADENOVIRUS 6 VACCINE; CHIMPANZEE ADENOVIRUS 7 VACCINE; DNA VACCINE; HLA DR ANTIGEN; HUMAN ADENOVIRUS 5 VACCINE; KI 67 ANTIGEN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIGEN; GAG PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ADENOVIRIDAE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMPANZEE ADENOVIRUS 6; CHIMPANZEE ADENOVIRUS 7; CONTROLLED STUDY; ELECTROPORATION; HUMAN ADENOVIRUS 5; NONHUMAN; PRIORITY JOURNAL; RECTUM; RECTUM BIOPSY; RECTUM MUCOSA; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS; VIREMIA; VIRUS LOAD; ANIMAL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MUCOSAL IMMUNITY; PATHOGENICITY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ANIMALIA; CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, GAG; GENE PRODUCTS, TAT; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; LYMPHOCYTE ACTIVATION; MACACA MULATTA; RECEPTORS, CCR5; RECTUM; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; VACCINATION; VIREMIA;

EID: 84920972934     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1407466112     Document Type: Article

References (37)

1. Koup RA, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68(7):4650-4655.
2. Letvin NL (2007) Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 27(3):366-369.
3. Betts MR, et al. (2006) HIV non progress sors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107(12):4781-4789.
4. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68(9):6103-6110.
5. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8(8):619-630.
6. Schmitz JE, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283(5403):857-860.
7. Matano T, et al. (1998) Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72(1):164-169.
8. Jin X, et al. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189(6):991-998.
9. Klatt NR, et al. (2010) CD8+ lymphocytes control viral replication in SIVmac239- infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 6(1):e1000747.
10. Burton DR, et al. (2012) A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12(4):396-407.
11. Garber DA, Silvestri G, Feinberg MB (2004) Prospects for an AIDS vaccine: Three big questions, no easy answers. Lancet Infect Dis 4(7):397-413.
12. Qureshi H, et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86(4):2239-2250.
13. Buchbinder SP, et al.; Step Study Protocol Team (2008) Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881-1893.
14. Hammer SM, et al. (2013) Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369(22):2083-2092.
15. Gray GE, et al.; HVTN 503/Phambili study team (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7):507-515.
16. Picker LJ, Hansen SG, Lifson JD (2012) New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63:95-111.
17. Haynes BF, McElrath MJ (2013) Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 8(4):326-332.
18. Fukazawa Y, et al. (2012) Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18(11):1673-1681.
19. Hansen SG, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15(3):293-299.
20. Vogel TU, et al. (2003) Multi specific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 77(24):13348-13360.
21. Engram JC, et al. (2009) Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol 183(1):706-717.
22. Barouch DH, et al. (2009) Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 83(18):9584-9590.
23. Casimiro DR, et al. (2010) Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 84(6):2996-3003.
24. Cervasi B, et al. (2013) Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing SIVgag/tat and challenged intra- rectally with repeated low-dose of SIVmac. J Virol 87(17):9420-9430.
25. Casimiro DR, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79(24):15547-15555.
26. Wilson NA, et al. (2006) Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80(12):5875-5885.
27. Tatsis N, et al. (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13(5):421-429.
28. Hansen SG, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348):523-527.
29. Letvin NL, et al. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 3(81):81ra36.
30. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
31. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.
32. Zhou D, et al. (2010) An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5(11):1775-1785.
33. Yan J, et al. (2009) Novel SIV mac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine 27(25-26):3260-3266.
34. Laddy DJ, et al. (2008) Hetero subtypic protection against pathogenic human and avian influenza viruses via in vivo electro poration of synthetic consensus DNA antigens. PLoS ONE 3(6):e2517.
35. Gordon SN, et al. (2007) Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 179(5):3026-3034.
36. Altman JD, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284):94-96.
37. Silvestri G, et al. (2003) Nonpathogenic SIV infection of sooty manga beys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18(3):441-452.